Tesla plans to expand car parts production capacity in Shanghai: government document

This post was originally published on this site

By Yilei Sun and Brenda Goh

BEIJING (Reuters) – Tesla Inc (O:) plans to increase its production capacity for certain car parts at its $2 billion factory in China, according to a government document seen by Reuters, as it pushes to localize its supply chain in the world’s biggest auto market.

The U.S. automaker, which started delivering Model 3 electric sedans from its Shanghai factory in December, plans to add lines to make more battery packs, electric motors, and motor controllers, according to the document submitted by Tesla to Shanghai government.

Tesla, which as of end-December used about 70% imported parts for the cars it made in China, did not immediately respond to a Reuters request for comment.

But according to the document, Tesla wants to almost double its annual building capacity for cooling pipes, a key part in a car’s heat management system, to 260,000 sets a year from 150,000. It did not provide capacity details for other parts.

The planned production line will not include battery cell manufacturing but will package out-sourced battery cells at the plant, the document said.

Tesla has previously said it wants to localize its entire supply chain in China by the end of this year.

The company is also building an additional stamping line to speed up car production in Shanghai, according to construction documents seen by Reuters.

The Shanghai factory is key to Tesla’s growth strategy. There it aims to produce 150,000 Model 3 sedans and later hike output to 250,000 a year, including the Model Y, according to a Shanghai government filing in 2018.

The company aims to deliver more than 500,000 vehicles globally by end-2020.

Tesla’s production and delivery plans in Shanghai, however, have been disrupted by a coronavirus outbreak that has killed more than 3,100 people in the world’s No.2 economy. Passenger car retail sales in China plunged around 80% in February due to the epidemic, industry data shows.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.